Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial.
Prasmickaite L, Berge G, Bettum IJ, Aamdal S, Hansson J, Bastholt L, Øijordsbakken M, Boye K, Mælandsmo GM. Prasmickaite L, et al. Among authors: hansson j. Cancer Immunol Immunother. 2015 Jun;64(6):769-76. doi: 10.1007/s00262-015-1686-4. Epub 2015 Apr 2. Cancer Immunol Immunother. 2015. PMID: 25832001 Free PMC article.
Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels.
Vihinen P, Tervahartiala T, Sorsa T, Hansson J, Bastholt L, Aamdal S, Stierner U, Pyrhönen S, Syrjänen K, Lundin J, Hernberg M. Vihinen P, et al. Among authors: hansson j. Cancer Immunol Immunother. 2015 Feb;64(2):173-80. doi: 10.1007/s00262-014-1620-1. Epub 2014 Oct 16. Cancer Immunol Immunother. 2015. PMID: 25319807 Free PMC article. Clinical Trial.
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM; EORTC Melanoma Group and the Nordic Melanoma Group. Bouwhuis MG, et al. Among authors: hansson j. J Natl Cancer Inst. 2009 Jun 16;101(12):869-77. doi: 10.1093/jnci/djp132. Epub 2009 Jun 9. J Natl Cancer Inst. 2009. PMID: 19509353
Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.
Brandberg Y, Johansson H, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J; Nordic Melanoma Cooperative Group. Brandberg Y, et al. Among authors: hansson j. Acta Oncol. 2013 Aug;52(6):1086-93. doi: 10.3109/0284186X.2013.789140. Epub 2013 Apr 28. Acta Oncol. 2013. PMID: 23621752 Clinical Trial.
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group. Hansson J, et al. Lancet Oncol. 2011 Feb;12(2):144-52. doi: 10.1016/S1470-2045(10)70288-6. Epub 2011 Jan 20. Lancet Oncol. 2011. PMID: 21256809 Clinical Trial.
Species-specific in vivo engraftment of the human BL melanoma cell line results in an invasive dedifferentiated phenotype not present in xenografts.
Cedervall J, Jamil S, Prasmickaite L, Cheng Y, Eskandarpour M, Hansson J, Maelandsmo GM, Ringborg U, Gulyas M, Zhen HS, Kanter L, Ahrlund-Richter L. Cedervall J, et al. Among authors: hansson j. Cancer Res. 2009 May 1;69(9):3746-54. doi: 10.1158/0008-5472.CAN-08-3746. Epub 2009 Apr 21. Cancer Res. 2009. PMID: 19383913
Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group. Krogh M, et al. Among authors: hansson j. Melanoma Res. 2016 Aug;26(4):367-76. doi: 10.1097/CMR.0000000000000237. Melanoma Res. 2016. PMID: 27076041 Clinical Trial.
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.
Ascierto PA, Bastholt L, Ferrucci PF, Hansson J, Márquez Rodas I, Payne M, Robert C, Thomas L, Utikal JS, Wolter P, Kudlac A, Tuson H, McKendrick J. Ascierto PA, et al. Among authors: hansson j. Melanoma Res. 2018 Aug;28(4):333-340. doi: 10.1097/CMR.0000000000000455. Melanoma Res. 2018. PMID: 29750751 Free PMC article.
471 results